Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis

Authors

Ravish Parekh, Henry Ford Health
Ahmed Abdulhamid, Henry Ford HealthFollow
Sheri Trudeau, Henry Ford HealthFollow
Nirmal Kaur, Henry Ford HealthFollow

Recommended Citation

Case Rep Gastrointest Med 2018; 2018:1015408.

Document Type

Article

Publication Date

1-1-2018

Publication Title

Case Rep Gastrointest Med

Abstract

Outcome data regarding the use of tumor necrosis factor alpha inhibitors (anti-TNFα) in patients with inflammatory bowel disease (IBD) after liver transplant (LT) for primary sclerosing cholangitis (PSC) are scant.

PubMed ID

29862092

Volume

2018

First Page

1015408